- Home
- ISPR vs SGHT Comparison
ISPR vs SGHT Comparison
Compare ISPR & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPR
- SGHT
- Stock Information
- Founded
- ISPR 2019
- SGHT 2011
- Country
- ISPR United States
- SGHT United States
- Employees
- ISPR N/A
- SGHT N/A
- Industry
- ISPR Medicinal Chemicals and Botanical Products
- SGHT Medical Specialities
- Sector
- ISPR Health Care
- SGHT Health Care
- Exchange
- ISPR Nasdaq
- SGHT Nasdaq
- Market Cap
- ISPR 170.1M
- SGHT 140.1M
- IPO Year
- ISPR 2023
- SGHT 2021
- Fundamental
- Price
- ISPR $3.03
- SGHT $3.03
- Analyst Decision
- ISPR Strong Buy
- SGHT Buy
- Analyst Count
- ISPR 2
- SGHT 7
- Target Price
- ISPR $10.75
- SGHT $3.92
- AVG Volume (30 Days)
- ISPR 35.8K
- SGHT 161.2K
- Earning Date
- ISPR 05-16-2025
- SGHT 05-08-2025
- Dividend Yield
- ISPR N/A
- SGHT N/A
- EPS Growth
- ISPR N/A
- SGHT N/A
- EPS
- ISPR N/A
- SGHT N/A
- Revenue
- ISPR $148,524,656.00
- SGHT $78,109,000.00
- Revenue This Year
- ISPR $6.22
- SGHT N/A
- Revenue Next Year
- ISPR $36.16
- SGHT $11.17
- P/E Ratio
- ISPR N/A
- SGHT N/A
- Revenue Growth
- ISPR 5.10
- SGHT N/A
- 52 Week Low
- ISPR $2.50
- SGHT $2.03
- 52 Week High
- ISPR $8.40
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- ISPR 49.72
- SGHT 56.13
- Support Level
- ISPR $2.78
- SGHT $2.81
- Resistance Level
- ISPR $3.00
- SGHT $3.26
- Average True Range (ATR)
- ISPR 0.24
- SGHT 0.24
- MACD
- ISPR 0.03
- SGHT -0.01
- Stochastic Oscillator
- ISPR 51.89
- SGHT 38.57
About ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping in the United States, Europe, Canada, and South Africa.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.